Los Angeles Capital Management LLC increased its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 942.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 145,930 shares of the company’s stock after buying an additional 131,934 shares during the period. Los Angeles Capital Management LLC owned 0.32% of Pacira BioSciences worth $2,196,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in shares of Pacira BioSciences by 229.6% in the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock worth $38,000 after acquiring an additional 932 shares during the last quarter. Park Place Capital Corp bought a new position in Pacira BioSciences in the 2nd quarter worth approximately $46,000. Innealta Capital LLC acquired a new position in Pacira BioSciences during the 2nd quarter worth $50,000. nVerses Capital LLC boosted its position in Pacira BioSciences by 800.0% in the 2nd quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock valued at $51,000 after buying an additional 1,600 shares during the last quarter. Finally, Natixis acquired a new stake in shares of Pacira BioSciences in the 1st quarter valued at $95,000. Institutional investors own 99.73% of the company’s stock.
Pacira BioSciences Trading Down 2.1 %
NASDAQ PCRX opened at $16.45 on Thursday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The stock’s 50-day moving average is $15.69 and its 200-day moving average is $20.81. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $35.95. The firm has a market cap of $759.55 million, a P/E ratio of -8.10 and a beta of 0.82.
Wall Street Analyst Weigh In
View Our Latest Stock Analysis on PCRX
Pacira BioSciences Profile
Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.
Featured Articles
- Five stocks we like better than Pacira BioSciences
- What is a Dividend King?
- Rocket Lab is the Right Stock for the Right Time
- With Risk Tolerance, One Size Does Not Fit All
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- What Are the FAANG Stocks and Are They Good Investments?
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report).
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.